As per the research report titled ‘Global Peptide Therapeutics Market (2021 Edition) - Analysis By Drug Type (Generic, Innovative), Manufacturing Type (In-House, Outsourced), Application,, By Region, By Country: Market Insights, Covid-19 Impact, Competition and Forecast (2021-2026)’, available with MarketStudyReport, global peptide therapeutics market was valued USD 32.1 billion in 2020 and is anticipated to grow considerably over the forecast timeframe 2021-2026.

Global peptide therapeutics market is driven by rising burden of cancer, increasing healthcare expenditure, escalating cases of metabolic disorders, geriatric population boom, and accelerated approval of new therapeutic drugs. Besides, rising number of collaborations between pharmaceutical companies and biotechnology firms are enhancing the industry outlook.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4226455/  

Notably, biologics has gained considerable traction over the last few years. Peptide therapeutics has shifted focus of the healthcare sector from conventional small molecule-based intervention to new and complex pharmacological interventions. High target specificity, favorable safety profiles, and low toxicity are the major benefits encouraging the adoption of these therapeutics.

Considering the drug type, the industry is split into generic and innovative. With respect to manufacturing type, the market is split into outsourced and in-house. Speaking of application, the segmentation comprises oncology, metabolic, cardiovascular, gastrointestinal, neurological, and others.

In terms of regional bifurcation, North America (United States, Canada), Europe (Germany, Spain, United Kingdom, Italy), and Asia Pacific (South Korea, Japan, China) majorly define global peptide therapeutics industry size and scope.

North America market is anticipated to record strong gains in the upcoming years, creditable to factors such as increasing R&D expenditure by government and key players, high prevalence of cancer and other diseases, and presence of a well-established biopharmaceutical and pharmaceutical industry in the region.

Coming to the competitive landscape, Bristol-Mayer Squibb Co., Takeda Pharmaceutical Co. Ltd., Amgen Inc, Novo Nordisk A/S, AstraZeneca plc, Eli Lily and Company, GlaxoSmithKline plc, Pfizer Inc., and Novartis AG are the major players influencing the industry dynamics.